Search alternatives:
reduction decrease » reduction decreased (Expand Search), reduction reuse (Expand Search), production increases (Expand Search)
point decrease » point increase (Expand Search)
non decrease » nn decrease (Expand Search), note decreased (Expand Search), fold decrease (Expand Search)
Showing 121 - 140 results of 24,806 for search '(( significant ((non decrease) OR (point decrease)) ) OR ( significant reduction decrease ))', query time: 1.22s Refine Results
  1. 121
    Switching patterns of ICS/LABA.

    Switching patterns of ICS/LABA. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  2. 122
    Factors associated with exacerbations.

    Factors associated with exacerbations. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  3. 123
    Definition of each exacerbation.

    Definition of each exacerbation. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  4. 124
    Definitions of treatment step classification.

    Definitions of treatment step classification. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  5. 125
    Sensitivity analyses of breakthrough exacerbations.

    Sensitivity analyses of breakthrough exacerbations. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  6. 126
    Baseline characteristics of patients.

    Baseline characteristics of patients. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  7. 127
    Data for primary and sensitivity analysis.

    Data for primary and sensitivity analysis. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  8. 128
    Study design.

    Study design. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 129
    Odds ratios for each case period compared with the control period.

    Odds ratios for each case period compared with the control period. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  10. 130
    Sensitivity analysis of the group who had an exacerbation before the index date.

    Sensitivity analysis of the group who had an exacerbation before the index date. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  11. 131
    Initial post-switch visits and SABA prescriptions in each period.

    Initial post-switch visits and SABA prescriptions in each period. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  12. 132
    Flow of eligible patients.

    Flow of eligible patients. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  13. 133
    ICS/LABA before and after switch.

    ICS/LABA before and after switch. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  14. 134
    Diseases excluded from the analysis.

    Diseases excluded from the analysis. by Rieko Kondo (10010647)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  15. 135
    Image3_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.TIF

    Image3_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.TIF by Sandra Torres (3361256)

    Published 2021
    Save to List
    Saved in:
  16. 136
    Image2_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.JPEG

    Image2_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.JPEG by Sandra Torres (3361256)

    Published 2021
    Save to List
    Saved in:
  17. 137
    Image4_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.TIF

    Image4_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.TIF by Sandra Torres (3361256)

    Published 2021
    Save to List
    Saved in:
  18. 138
    Image1_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.TIF

    Image1_The Specific NLRP3 Antagonist IFM-514 Decreases Fibrosis and Inflammation in Experimental Murine Non-Alcoholic Steatohepatitis.TIF by Sandra Torres (3361256)

    Published 2021
    Save to List
    Saved in:
  19. 139
    Magnitude of emission reduction.

    Magnitude of emission reduction. by Mohammed Qasim Shaheen (21417079)

    Published 2025
    “…In addition, the results examine a significant reduction in CO<sub>2</sub> emissions by 1.58 kg/hr. …”
    Save to List
    Saved in:
  20. 140
    Decreased Paneth cell number and the presence of granulomas differentiate HbTg from Tg animals at 10 days post Tg infection.

    Decreased Paneth cell number and the presence of granulomas differentiate HbTg from Tg animals at 10 days post Tg infection. by Edina K. Szabo (3160332)

    Published 2024
    Save to List
    Saved in:

Search Tools: